SG10201608577RA - Salt form of a human hi stone methyltransf erase ezh2 inhibitor - Google Patents
Salt form of a human hi stone methyltransf erase ezh2 inhibitorInfo
- Publication number
- SG10201608577RA SG10201608577RA SG10201608577RA SG10201608577RA SG10201608577RA SG 10201608577R A SG10201608577R A SG 10201608577RA SG 10201608577R A SG10201608577R A SG 10201608577RA SG 10201608577R A SG10201608577R A SG 10201608577RA SG 10201608577R A SG10201608577R A SG 10201608577RA
- Authority
- SG
- Singapore
- Prior art keywords
- stone
- human
- salt form
- ezh2 inhibitor
- methyltransf erase
- Prior art date
Links
- 101150090105 Ezh2 gene Proteins 0.000 title 1
- 102000016397 Methyltransferase Human genes 0.000 title 1
- 108060004795 Methyltransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
- 239000004575 stone Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624215P | 2012-04-13 | 2012-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201608577RA true SG10201608577RA (en) | 2016-12-29 |
Family
ID=49328166
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201608577RA SG10201608577RA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| SG10201912109QA SG10201912109QA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| SG11201406468YA SG11201406468YA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912109QA SG10201912109QA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| SG11201406468YA SG11201406468YA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US9394283B2 (en) |
| EP (4) | EP3184523B1 (en) |
| JP (3) | JP6255382B2 (en) |
| KR (4) | KR20250005505A (en) |
| CN (2) | CN108358899B (en) |
| AU (2) | AU2013245878B2 (en) |
| BR (1) | BR112014025508B1 (en) |
| CA (1) | CA2870005C (en) |
| CY (2) | CY1119383T1 (en) |
| DK (3) | DK2836491T3 (en) |
| ES (3) | ES2745016T3 (en) |
| HR (2) | HRP20170295T1 (en) |
| HU (3) | HUE031976T2 (en) |
| IL (4) | IL282732B2 (en) |
| IN (1) | IN2014DN09068A (en) |
| LT (2) | LT2836491T (en) |
| MX (2) | MX384641B (en) |
| NZ (1) | NZ700761A (en) |
| PL (3) | PL2836491T3 (en) |
| PT (3) | PT2836491T (en) |
| RS (2) | RS55690B1 (en) |
| RU (1) | RU2658911C2 (en) |
| SG (3) | SG10201608577RA (en) |
| SI (2) | SI2836491T1 (en) |
| SM (2) | SMT201900501T1 (en) |
| WO (1) | WO2013155317A1 (en) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Heteroaryl or aryl substituted gasoline compounds |
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| NZ628762A (en) | 2012-02-10 | 2016-07-29 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP6340361B2 (en) | 2012-04-13 | 2018-06-06 | エピザイム，インコーポレイティド | Combination therapy to treat cancer |
| DK2836491T3 (en) * | 2012-04-13 | 2017-03-06 | Epizyme Inc | SALT FORM OF A HUMAN HISTONMETHYL TRANSFERASE EZH2 INHIBITOR |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| KR102021642B1 (en) * | 2012-10-15 | 2019-09-16 | 에피자임, 인코포레이티드 | Methods of treating cancer |
| CN105102432B (en) * | 2012-10-15 | 2019-01-04 | Epizyme股份有限公司 | The benzene compound being substituted |
| WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| SG11201508203TA (en) | 2013-04-30 | 2015-11-27 | Glaxosmithkline Ip No 2 Ltd | Enhancer of zeste homolog 2 inhibitors |
| JP2016523955A (en) | 2013-07-10 | 2016-08-12 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ | ZESTE homolog 2 enhancer inhibitor |
| WO2015023915A1 (en) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| CN105829302B (en) | 2013-10-16 | 2020-09-08 | Epizyme股份有限公司 | Hydrochloride salt form for EZH2 inhibition |
| AU2014337121A1 (en) * | 2013-10-18 | 2016-04-14 | Epizyme, Inc. | Method of treating cancer |
| US9738630B2 (en) | 2013-11-19 | 2017-08-22 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| EP3888659A1 (en) | 2013-12-06 | 2021-10-06 | Epizyme Inc | Combination therapy for treating cancer |
| IL285201B2 (en) | 2014-06-17 | 2024-05-01 | Epizyme Inc | Ezh2 inhibitors for treating lymphoma |
| CA2952830C (en) | 2014-06-20 | 2022-11-01 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
| JP2017532338A (en) | 2014-10-16 | 2017-11-02 | エピザイム，インコーポレイティド | How to treat cancer |
| EP3220916B1 (en) * | 2014-11-17 | 2023-04-19 | Epizyme, Inc. | Method for treating cancer with n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl) amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide |
| AR102767A1 (en) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | EZH2 INHIBITORS |
| SG11201708286PA (en) | 2015-04-20 | 2017-11-29 | Epizyme Inc | Combination therapy for treating cancer |
| MX387885B (en) | 2015-06-10 | 2025-03-19 | Epizyme Inc | Ezh2 inhibitors for treating lymphoma |
| CA2996412A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| TW201718598A (en) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Inhibitors of EZH2 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| WO2017132518A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| MA45406A (en) | 2016-06-17 | 2019-04-24 | Epizyme Inc | EZH2 INHIBITORS TO TREAT CANCER |
| EP3529242A1 (en) | 2016-10-19 | 2019-08-28 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| US11214561B2 (en) * | 2017-01-25 | 2022-01-04 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2018275123A1 (en) | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| EP3678663A4 (en) | 2017-09-05 | 2021-06-02 | Epizyme, Inc. | COMBINATION THERAPY FOR TREATMENT OF CANCER |
| EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| EP4017527A1 (en) | 2019-08-22 | 2022-06-29 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| EP4077314A1 (en) * | 2019-12-20 | 2022-10-26 | Epizyme, Inc. | Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer |
| WO2022208552A1 (en) * | 2021-03-31 | 2022-10-06 | Msn Laboratories Private Limited, R&D Center | Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733729A (en) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Production of n-cyano-n'-substituted-arylcarboxyimidamide compound |
| AU694465B2 (en) | 1993-12-27 | 1998-07-23 | Eisai Co. Ltd. | Anthranilic acid derivative |
| DE19516776A1 (en) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin regulatory genes |
| US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| JP3906935B2 (en) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | N-substituted dioxothiazolidylbenzamide derivative and process for producing the same |
| AU6060099A (en) | 1998-09-30 | 2000-04-17 | Procter & Gamble Company, The | 2-substituted ketoamides |
| UA71587C2 (en) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Anthranilic acid amides and use thereof as medicaments |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| JP4137636B2 (en) | 2000-12-28 | 2008-08-20 | 塩野義製薬株式会社 | Pyridone derivatives having cannabinoid type 2 receptor affinity |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| DE60329981D1 (en) | 2002-02-19 | 2009-12-24 | Shionogi & Co | antipruritics |
| TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
| US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
| JP2007531757A (en) | 2004-03-30 | 2007-11-08 | カイロン コーポレイション | Substituted thiophene derivatives as anticancer agents |
| US7563589B2 (en) | 2004-06-01 | 2009-07-21 | The University Of North Carolina At Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
| ATE494548T1 (en) | 2005-06-02 | 2011-01-15 | Univ North Carolina | PURIFICATION, CHARACTERIZATION AND RECOVERY OF A UBIQUITIN E3 LIGASE |
| FR2889526B1 (en) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE |
| PL1940821T3 (en) | 2005-10-19 | 2013-08-30 | Gruenenthal Gmbh | Novel vanilloid receptor ligands and their use for producing medicaments |
| CN101291910A (en) | 2005-10-21 | 2008-10-22 | 默克公司 | Potassium channel inhibitors |
| WO2007053480A2 (en) | 2005-10-28 | 2007-05-10 | The University Of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
| CN101341124A (en) | 2005-12-14 | 2009-01-07 | 布里斯托尔-迈尔斯斯奎布公司 | Six-membered heterocycles useful as serine protease inhibitors |
| AU2006336552B2 (en) | 2006-01-20 | 2012-12-20 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
| RU2008149246A (en) | 2006-05-15 | 2010-06-20 | Айрм Ллк (Bm) | TERPHTHALATE BASED COMPOUND, COMPOSITIONS AND THEIR APPLICATION AS HIV INTEGRAS INHIBITORS |
| EP2040711A2 (en) | 2006-05-18 | 2009-04-01 | Amphora Discovery Corporation | 2-oxo-1,2-dihydroquinoline derivatives, compositions, and uses thereof as antiproliferative agents |
| EP2086318A4 (en) | 2006-10-10 | 2009-12-23 | Burnham Inst Medical Research | NEUROPROTEKTIVE COMPOSITIONS AND METHOD |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DE102007017884A1 (en) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Novel vanilloid receptor ligands and their use in the preparation of medicines |
| US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
| DE102007047737A1 (en) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidine and piperazine derivatives |
| US8247401B2 (en) | 2007-10-31 | 2012-08-21 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| MX2010006739A (en) | 2007-12-19 | 2010-10-08 | Cancer Rec Tech Ltd | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use. |
| WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| AU2009279616A1 (en) | 2008-08-08 | 2010-02-11 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
| FR2934995B1 (en) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | POLYSUBSTITUTED AZETIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF |
| JP2012522013A (en) | 2009-03-27 | 2012-09-20 | ザ ユーエービー リサーチ ファウンデーション | Regulated IRES-mediated translation |
| US20110021362A1 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| EP2521558A4 (en) | 2009-12-30 | 2013-07-03 | Avon Prod Inc | Topical lightening composition and uses thereof |
| LT2566327T (en) | 2010-05-07 | 2017-05-25 | Glaxosmithkline Llc | Indoles |
| US8637509B2 (en) * | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| US8846935B2 (en) * | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
| AU2011298987B2 (en) | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5908493B2 (en) | 2010-12-01 | 2016-04-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | Indole |
| EP2646454B1 (en) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TWI598336B (en) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | Substituted benzene compounds |
| JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Heteroaryl or aryl substituted gasoline compounds |
| AU2013232229B2 (en) | 2012-03-12 | 2017-11-23 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| DK2836491T3 (en) | 2012-04-13 | 2017-03-06 | Epizyme Inc | SALT FORM OF A HUMAN HISTONMETHYL TRANSFERASE EZH2 INHIBITOR |
| JP6340361B2 (en) | 2012-04-13 | 2018-06-06 | エピザイム，インコーポレイティド | Combination therapy to treat cancer |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| KR102021642B1 (en) | 2012-10-15 | 2019-09-16 | 에피자임, 인코포레이티드 | Methods of treating cancer |
| CN105829302B (en) | 2013-10-16 | 2020-09-08 | Epizyme股份有限公司 | Hydrochloride salt form for EZH2 inhibition |
-
2013
- 2013-04-11 DK DK13774979.2T patent/DK2836491T3/en active
- 2013-04-11 MX MX2019000449A patent/MX384641B/en unknown
- 2013-04-11 AU AU2013245878A patent/AU2013245878B2/en active Active
- 2013-04-11 RS RS20170198A patent/RS55690B1/en unknown
- 2013-04-11 US US14/394,431 patent/US9394283B2/en active Active
- 2013-04-11 RU RU2014145544A patent/RU2658911C2/en not_active Application Discontinuation
- 2013-04-11 EP EP16191716.6A patent/EP3184523B1/en active Active
- 2013-04-11 HU HUE13774979A patent/HUE031976T2/en unknown
- 2013-04-11 SM SM20190501T patent/SMT201900501T1/en unknown
- 2013-04-11 JP JP2015505912A patent/JP6255382B2/en active Active
- 2013-04-11 DK DK16191716.6T patent/DK3184523T3/en active
- 2013-04-11 ES ES16191716T patent/ES2745016T3/en active Active
- 2013-04-11 BR BR112014025508-3A patent/BR112014025508B1/en active IP Right Grant
- 2013-04-11 KR KR1020247041285A patent/KR20250005505A/en active Pending
- 2013-04-11 DK DK19180479.8T patent/DK3628670T3/en active
- 2013-04-11 IL IL282732A patent/IL282732B2/en unknown
- 2013-04-11 SG SG10201608577RA patent/SG10201608577RA/en unknown
- 2013-04-11 MX MX2014012380A patent/MX362339B/en active IP Right Grant
- 2013-04-11 CA CA2870005A patent/CA2870005C/en active Active
- 2013-04-11 EP EP22200677.7A patent/EP4190777A1/en active Pending
- 2013-04-11 LT LTEP13774979.2T patent/LT2836491T/en unknown
- 2013-04-11 HR HRP20170295TT patent/HRP20170295T1/en unknown
- 2013-04-11 EP EP19180479.8A patent/EP3628670B1/en active Active
- 2013-04-11 HU HUE16191716A patent/HUE045353T2/en unknown
- 2013-04-11 EP EP13774979.2A patent/EP2836491B1/en active Active
- 2013-04-11 RS RSP20191175 patent/RS59392B1/en unknown
- 2013-04-11 WO PCT/US2013/036193 patent/WO2013155317A1/en active Application Filing
- 2013-04-11 CN CN201810245662.3A patent/CN108358899B/en active Active
- 2013-04-11 PT PT137749792T patent/PT2836491T/en unknown
- 2013-04-11 SG SG10201912109QA patent/SG10201912109QA/en unknown
- 2013-04-11 PT PT16191716T patent/PT3184523T/en unknown
- 2013-04-11 HU HUE19180479A patent/HUE060881T2/en unknown
- 2013-04-11 PL PL13774979T patent/PL2836491T3/en unknown
- 2013-04-11 PL PL16191716T patent/PL3184523T3/en unknown
- 2013-04-11 LT LTEP16191716.6T patent/LT3184523T/en unknown
- 2013-04-11 SI SI201330551A patent/SI2836491T1/en unknown
- 2013-04-11 KR KR1020147030684A patent/KR102120883B1/en active Active
- 2013-04-11 SI SI201331566T patent/SI3184523T1/en unknown
- 2013-04-11 KR KR1020207015664A patent/KR102438340B1/en active Active
- 2013-04-11 CN CN201380030902.3A patent/CN104603130B/en active Active
- 2013-04-11 NZ NZ700761A patent/NZ700761A/en unknown
- 2013-04-11 SG SG11201406468YA patent/SG11201406468YA/en unknown
- 2013-04-11 ES ES19180479T patent/ES2931316T3/en active Active
- 2013-04-11 SM SM20170132T patent/SMT201700132T1/en unknown
- 2013-04-11 KR KR1020227029511A patent/KR102744039B1/en active Active
- 2013-04-11 ES ES13774979.2T patent/ES2617379T3/en active Active
- 2013-04-11 PL PL19180479.8T patent/PL3628670T3/en unknown
- 2013-04-11 IL IL296199A patent/IL296199B2/en unknown
- 2013-04-11 PT PT191804798T patent/PT3628670T/en unknown
- 2013-04-11 IN IN9068DEN2014 patent/IN2014DN09068A/en unknown
-
2014
- 2014-10-07 IL IL235045A patent/IL235045B/en active IP Right Grant
-
2016
- 2016-06-30 US US15/199,522 patent/US9872862B2/en active Active
-
2017
- 2017-03-06 CY CY20171100290T patent/CY1119383T1/en unknown
- 2017-10-12 JP JP2017198642A patent/JP6634058B2/en active Active
- 2017-12-11 US US15/837,390 patent/US10245269B2/en active Active
-
2018
- 2018-01-09 AU AU2018200168A patent/AU2018200168B2/en active Active
- 2018-10-02 JP JP2018187463A patent/JP2018199740A/en active Pending
-
2019
- 2019-02-08 US US16/270,752 patent/US10821113B2/en active Active
- 2019-04-21 IL IL266165A patent/IL266165B/en active IP Right Grant
- 2019-09-13 HR HRP20191653TT patent/HRP20191653T1/en unknown
- 2019-09-18 CY CY20191100981T patent/CY1122883T1/en unknown
-
2020
- 2020-09-25 US US17/032,432 patent/US11491163B2/en active Active
-
2022
- 2022-09-29 US US17/936,555 patent/US12251386B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266165B (en) | Salt form of a human hi stone methyltransf erase ezh2 inhibitor | |
| IL259958B (en) | Heterocyclic inhibitors of glutaminase | |
| IL232599A (en) | Hydrobromide salt of pridopidine | |
| EP2678018A4 (en) | Combination of kanase inhibitors and uses thereof | |
| IL230901A0 (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| IL232292A0 (en) | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors | |
| ZA201401417B (en) | Novel soft rock inhibitors | |
| PH12013502483A1 (en) | Use of a metal salt of 2-mercaptobenzothiazole | |
| ZA201307496B (en) | Novel rock inhibitors | |
| EP2760853A4 (en) | Novel salts of alogliptin | |
| EP2709999A4 (en) | Quinazoline-7-ether compounds and methods of use | |
| GB201114854D0 (en) | Novel rock inhibitors | |
| PT2709584T (en) | Sensory use of 6-cyclopentylidenehexane derivatives | |
| GB201117252D0 (en) | Improved treatment of hard surfaces | |
| ZA201205358B (en) | Use of a salt of bistetrazolylamine | |
| ZA201308872B (en) | Use of a dinitromethane salt |